State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu 210023, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau SAR.
Cell Rep. 2021 Feb 9;34(6):108706. doi: 10.1016/j.celrep.2021.108706.
Administration of probiotics to regulate the immune system is a potential anti-tumor strategy. However, oral administration of probiotics is ineffective because of the poor inhabitation of exogenous bacteria in host intestines. Here we report that smectite, a type of mineral clay and established anti-diarrhea drug, promotes expansion of probiotics (especially Lactobacillus) in the murine gut and subsequently elicits anti-tumor immune responses. The ion-exchangeable microstructure of smectite preferentially promotes lactic acid bacteria (LABs) to form biofilms on smectite in vitro and in vivo. In mouse models, smectite laden with LAB biofilms (Lactobacillus and Bifidobacterium) inhibits tumor growth (when used alone) and enhances the efficacy of chemotherapy or immunotherapy (when used in combination with either of them) by activating dendritic cells (DCs) via Toll-like receptor 2 (TLR2) signaling. Our findings suggest oral administration of smectite as a promising strategy to enrich probiotics in vivo for cancer immunotherapy.
将益生菌用于调节免疫系统是一种有潜力的抗肿瘤策略。然而，由于外源性细菌在宿主肠道中定植不良，口服益生菌是无效的。在这里，我们报告说，蒙脱石，一种矿物粘土和已确立的抗腹泻药物，促进益生菌（尤其是乳酸菌）在小鼠肠道中的扩张，并随后引发抗肿瘤免疫反应。蒙脱石的离子交换微观结构优先促进乳酸菌（LAB）在体内和体外的蒙脱石上形成生物膜。在小鼠模型中，负载 LAB 生物膜（乳酸杆菌和双歧杆菌）的蒙脱石通过 Toll 样受体 2（TLR2）信号激活树突状细胞（DC），抑制肿瘤生长（单独使用时），并增强化疗或免疫疗法的疗效（与其中任何一种联合使用时）。我们的研究结果表明，口服蒙脱石是一种有前途的策略，可以在体内富集益生菌用于癌症免疫疗法。
